So when is Jadicell going to start the phase 3 trial for severe covid-19?

TSOI_Ry
Posts: 75
Joined: Mon Jun 29, 2020 12:19 pm
Location: Seattle, Wa

Re: So when is Jadicell going to start the phase 3 trial for severe covid-19?

Post by TSOI_Ry »

“But”

Approximately 65 million individuals globally/CDC

https://www.cdc.gov/copd/index.html

65mil x $100k = $6,500,000,000,000 that’s Trillion. Likely that # to date has likely risen significantly (long Covid, etc). But I’ll leave that research for someone else.

This math is specific to COPD/Worldwide. Some might argue capturing that market 100% is unlikely. Ok. But, but, but...

Let’s continue with the most potent known UC-MSC stem cell. JadiCell. What about TBI/CTE?

https://www.cdc.gov/traumaticbraininjur ... gress.html

“Traumatic brain injury (TBI) is a leading cause of death and disability among children and young adults in the United States. Each year an estimated 1.5 million Americans sustain a TBI. As a consequence of these injuries:

230,000 people are hospitalized and survive.
50,000 people die.
80,000 to 90,000 people experience the onset of long-term disability.
As the cumulative result of past traumatic brain injuries, an estimated 5.3 million men, women, and children are living with a permanent TBI-related disability in the United States today.”

TBI: 5.3m x $100,000 = $530,000,000,000
This is the known US market presently. Globally, likely 5x this #, but I’ll let someone else dig that up.

What is CTE? Does the FDA have their arms around diagnosing CTE in living subjects? (When it matters...)

“The Company(TSOI), which possesses the only filed Investigational New Drug (IND) application for treatment of chronic traumatic encephalopathy (CTE) was requested by the FDA to perform a series of experiments confirming several of the known properties of the JadiCell™ stem cells. With the completion of these experiments, the Company is cautiously optimistic to be granted clearance to initiate this "first in class" new treatment approach for CTE.“

What says the CDC??
“How is CTE Diagnosed?
To diagnose CTE, doctors check the brain of a person [after he or she dies]. Doctors look for changes in the brain that happen in people with CTE.5 Through this process, doctors confirm whether the person had CTE or another disease,
such as Alzheimer’s disease, or no disease
at all.5 Given the limited understanding of CTE and its causes, doctors cannot diagnose CTE in a living person.”

https://www.cdc.gov/traumaticbraininjur ... et-508.pdf

https://markets.businessinsider.com/new ... 1030708938

You see, the CDC admits, the only known way to diagnose CTE is postmortem. TSI as an FDA accepted definition/IND 👇🏼

"The fact that the FDA accepted our definition of CTE as diagnosed in living patients is in our opinion, a major breakthrough" said Dr. James Veltmeyer, Chief Medical Officer of the Company. "The experiments conducted demonstrate safety of the JadiCells™ in several different systems. We applaud the diligence and high level of scrutiny that the FDA has applied to our clinical trial and look forward to utilizing this novel approach to addressing this serious unmet medical need."

There is no accurate known number of suffering CTE patients. For instance, 99% of NFL players autopsied in were found to have suffered from CTE postmortem.

https://www.science.org/content/article ... ve-disease

There’s a rather large legal battle ensuing between the players association and the NFL. “But....”

What about JadiCell/Schizophrenia?

"As stated in our previous press release regarding current FDA discussions on stem cells and CTE, we believe that the Company has positioned itself in understanding the FDA process. This will allow us to file and clear multiple INDs," said Timothy Dixon,”

https://www.prnewswire.com/news-release ... 87400.html

Magnitude and impact

“Schizophrenia affects 20 million people worldwide but is not as common as many other mental disorders. Schizophrenia also commonly starts earlier among men.

Schizophrenia is associated with considerable disability and may affect educational and occupational performance.

People with schizophrenia are 2 - 3 times more likely to die early than the general population (2). This is often due to physical illnesses, such as cardiovascular, metabolic and infectious diseases.

Stigma, discrimination and violation of human rights of people with schizophrenia is common.“

20mil x $100,000 = $2,000,000,000,000

https://www.who.int/news-room/fact-shee ... izophrenia

You see, what some people are saying, minus the butts, is that in the lungs in the brain there are a myriad opportunities even if fractional and percentage-based. If you have a high percentage chance of being cured from your disability, why would you ever fool around with half measures? So when someone says “Milly Billy TRILLY”...

It might be because they are doing the math. I won’t continue on, but this company has put in motion via Allogen Biologics to perfectly reproduce in mass their exclusively licensed JadiCell.

Maybe this information is informative, maybe it’s not. Regardless, competitively priced, high Efficacy, low side effect/low/no adverse effect cures are extremely rare.
Phase 3 approval re UC-MSC Stem Cell... that hasn’t happened yet. TSOI seems to stand alone...

Does Neal Riordan have a UC-MSC stem cell ready to go into FDA phase 3?
Are his cells as potent as JadiCell? I leave those questions for others to answer.

There is much more information here to consider than what I have quickly laid out. It should encourage any smart investor to look further. Understand the ramifications of a FDA phase 3 approval for commercialization of JadiCell/Lung pathologies. However, in this post, I haven’t even mentioned StemVacs-V iPSC. And that is the most exciting development these last 6 years, hands down.

I hope everyone had a merry Christmas!
TradersTrader🍻
“Through adversity, comes strength...”
User avatar
TimGDixon
Posts: 3163
Joined: Fri Jun 26, 2020 4:36 am

Re: So when is Jadicell going to start the phase 3 trial for severe covid-19?

Post by TimGDixon »

That was a great walk thru. StemVacs is the key to all of this. Everything is now made on that platform beginning with induced pluripotent stem cells that are differentiated into whatever we need from a JadiCell to a neuronal cell.

There is much more information here to consider than what I have quickly laid out. It should encourage any smart investor to look further. Understand the ramifications of a FDA phase 3 approval for commercialization of JadiCell/Lung pathologies. However, in this post, I haven’t even mentioned StemVacs-V iPSC. And that is the most exciting development these last 6 years, hands down.
curiousman
Posts: 26
Joined: Fri Dec 24, 2021 3:09 am

Re: So when is Jadicell going to start the phase 3 trial for severe covid-19?

Post by curiousman »

TSOI_Ry wrote: Sun Dec 26, 2021 12:10 am
You see, what some people are saying, minus the butts, is that in the lungs in the brain there are a myriad opportunities even if fractional and percentage-based. If you have a high percentage chance of being cured from your disability, why would you ever fool around with half measures? So when someone says “Milly Billy TRILLY”...

It might be because they are doing the math. I won’t continue on, but this company has put in motion via Allogen Biologics to perfectly reproduce in mass their exclusively licensed JadiCell.

Maybe this information is informative, maybe it’s not. Regardless, competitively priced, high Efficacy, low side effect/low/no adverse effect cures are extremely rare.
Phase 3 approval re UC-MSC Stem Cell... that hasn’t happened yet. TSOI seems to stand alone...

Does Neal Riordan have a UC-MSC stem cell ready to go into FDA phase 3?
Are his cells as potent as JadiCell? I leave those questions for others to answer.

There is much more information here to consider than what I have quickly laid out. It should encourage any smart investor to look further. Understand the ramifications of a FDA phase 3 approval for commercialization of JadiCell/Lung pathologies. However, in this post, I haven’t even mentioned StemVacs-V iPSC. And that is the most exciting development these last 6 years, hands down.

I hope everyone had a merry Christmas!
I'm curious have you read Dr. Neil Riordan's book (Stem Cell Therapy: a Rising Tide)? It's literally a $1 ebook on amazon. Man that book blew my fucking mind when I first read it back in early 2018!!!!! I highly recommend that book to anyone who wishes to understand the potential of umbilical cord MSCs, in the book Neil tells you how there were people suffering from congestive heart failure who had low ejection fraction numbers, the ejection fraction is how much blood your heart is pumping out, a normal ejection fraction is 50 to 75%, anyhow these people had ejection fractions that were less than 40 and 30 (one of them was even on a heart transplant list) and were continuing to get lower, eventually their hearts would stop pumping out blood altogether resulting in death. These people flew down to Panama to the Stem Cell Institute and got intravenous infusions of umbilical cord MSCs and lo and behold their ejection fractions went back to normal! Neil Riordan's book is full of amazing stories like that!

But still it's only anecdotal, I mean when I hear about what UC-MSCs can do it almost sounds too good to be true, and there is a saying that goes "A lot of times if it sounds too good to be true than it most likely it isn't". So are UC-MSCs the real deal? CAUSE IF SO THEN THIS STUFF IS GOING TO CHANGE THE WORLD!!!!!!

As it stands right now TSOI (by the way what does the O stand for in TSOI?) is the closest one to getting umbilical cord MSCs approved by the FDA, if so it will be historic!!!!! Did you know that you can use drugs off label? As long as the drug has been approved by the FDA you can then use said drug for other indications other than what is was originally intended for, so if JadiCell successfully passes this phase 3 trial then doctors could start using it for any condition they want, such as heart failure or autism or arthritis and so much more (which is called off label use).
User avatar
TimGDixon
Posts: 3163
Joined: Fri Jun 26, 2020 4:36 am

Re: So when is Jadicell going to start the phase 3 trial for severe covid-19?

Post by TimGDixon »

Whats below is from another thread you can read here viewtopic.php?p=3281#p3281 if you scroll through this list you will find Dr. Riordan is co-author on many of the papers listed below.

This is not an exhaustive list of published papers of Thomas E Ichim but is representative of the level of science and associated collaborators who all work with TSOI one way or the other. Everyone from Franco Marincola to Santosh Kesari to Famela Ramos to Christopher Mizer to Feng Lin to Hong Ma to Boris Reznik to Javier Lopez to Amit Patel to Wei Ping Min and others - this is the academic prowess that drives TSOI. If you just add up Ichim, Kesari, and Marincola they have more than a combined 1,300 peer reviewed papers published. Is it making sense yet?

Josephs SF, Ichim TE, Prince SM, Kesari S, Marincola FM, Escobedo AR, Jafri
A. Unleashing endogenous TNF-alpha as a cancer immunotherapeutic. J Transl Med.
2018 Aug 31;16(1):242. doi: 10.1186/s12967-018-1611-7. PMID: 30170620; PMCID:
PMC6119315.

Ichim TE, O'Heeron P, Kesari S. Fibroblasts as a practical alternative to
mesenchymal stem cells. J Transl Med. 2018 Jul 27;16(1):212. doi:
10.1186/s12967-018-1536-1. PMID: 30053821; PMCID: PMC6064181.

Lin F, Ichim TE, Pingle S, Jones LD, Kesari S, Ashili S. Mesenchymal stem
cells as living anti-inflammatory therapy for COVID-19 related acute respiratory
distress syndrome. World J Stem Cells. 2020 Oct 26;12(10):1067-1079. doi:
10.4252/wjsc.v12.i10.1067. PMID: 33178392; PMCID: PMC7596438.

Tao Z, Li S, Ichim TE, Yang J, Riordan N, Yenugonda V, Babic I, Kesari S.
Cellular immunotherapy of cancer: an overview and future directions.
Immunotherapy. 2017 Jun;9(7):589-606. doi: 10.2217/imt-2016-0086. PMID:
28595516.

Wagner SC, Riordan NH, Ichim TE, Szymanski J, Ma H, Perez JA, Lopez J, Plata-
Munoz JJ, Silva F, Patel AN, Kesari S. Safety of targeting tumor endothelial
cell antigens. J Transl Med. 2016 Apr 12;14:90. doi: 10.1186/s12967-016-0842-8.
PMID: 27071457; PMCID: PMC4830034.

Scarpone M, Kuebler D, Chambers A, De Filippo CM, Amatuzio M, Ichim TE, Patel
AN, Caradonna E. Isolation of clinically relevant concentrations of bone marrow
mesenchymal stem cells without centrifugation. J Transl Med. 2019 Jan
5;17(1):10. doi: 10.1186/s12967-018-1750-x. PMID: 30611285; PMCID: PMC6321705.

Dobrovolsky AP, Gedzun VR, Bogin VI, Ma D, Ichim TE, Sukhanova IA, Malyshev
AV, Dubynin VA. Beneficial effects of xenon inhalation on behavioral changes in
a valproic acid-induced model of autism in rats. J Transl Med. 2019 Dec
3;17(1):400. doi: 10.1186/s12967-019-02161-6. PMID: 31796043; PMCID: PMC6891980.

Alexandrescu DT, Riordan NH, Ichim TE, Kauffman CL, Kabigting F, Dutton CT,
Dasanu CA. On the missing link between inflammation and cancer. Dermatol Online
J. 2011 Jan 15;17(1):10. PMID: 21272501.

Wagner SC, Ichim TE, Ma H, Szymanski J, Perez JA, Lopez J, Bogin V, Patel
AN, Marincola FM, Kesari S. Cancer anti-angiogenesis vaccines: Is the tumor
vasculature antigenically unique? J Transl Med. 2015 Oct 29;13:340. doi:
10.1186/s12967-015-0688-5. PMID: 26510973; PMCID: PMC4625691.

Maslin B, Alexandrescu DT, Ichim TE, Dasanu CA. Newer developments in the
immunotherapy of malignant melanoma. J Oncol Pharm Pract. 2014 Feb;20(1):3-10.
doi: 10.1177/1078155212472702. Epub 2013 Feb 22. PMID: 23435643.

Ichim TE, Zheng X, Suzuki M, Kubo N, Zhang X, Min LR, Beduhn ME, Riordan NH,
Inman RD, Min WP. Antigen-specific therapy of rheumatoid arthritis. Expert Opin
Biol Ther. 2008 Feb;8(2):191-9. doi: 10.1517/14712598.8.2.191. PMID: 18194075.

Mizer JC, Ichim TE, Alexandrescu DT, Dasanu CA, Ramos F, Turner A, Woods EJ,
Bogin V, Murphy MP, Koos D, Patel AN. Exogenous endothelial cells as
accelerators of hematopoietic reconstitution. J Transl Med. 2012 Nov 21;10:231.
doi: 10.1186/1479-5876-10-231. PMID: 23171397; PMCID: PMC3543295.

Ichim TE, Solano F, Glenn E, Morales F, Smith L, Zabrecky G, Riordan NH.
Stem cell therapy for autism. J Transl Med. 2007 Jun 27;5:30. doi:
10.1186/1479-5876-5-30. PMID: 17597540; PMCID: PMC1914111.

Alexandrescu DT, Ichim TE, Riordan NH, Marincola FM, Di Nardo A, Kabigting
FD, Dasanu CA. Immunotherapy for melanoma: current status and perspectives. J
Immunother. 2010 Jul-Aug;33(6):570-90. doi: 10.1097/CJI.0b013e3181e032e8. PMID:
20551839; PMCID: PMC3517185.

Li M, Qian H, Ichim TE, Ge WW, Popov IA, Rycerz K, Neu J, White D, Zhong R,
Min WP. Induction of RNA interference in dendritic cells. Immunol Res.
2004;30(2):215-30. doi: 10.1385/IR:30:2:215. PMID: 15477662.

Ichim TE, Li M, Qian H, Popov IA, Rycerz K, Zheng X, White D, Zhong R, Min
WP. RNA interference: a potent tool for gene-specific therapeutics. Am J
Transplant. 2004 Aug;4(8):1227-36. doi: 10.1111/j.1600-6143.2004.00530.x. PMID:
15268723; PMCID: PMC7175948.

Dasanu CA, Ichim TE, Alexandrescu DT. Inherent and iatrogenic immune defects
in hairy cell leukemia: revisited. Expert Opin Drug Saf. 2010 Jan;9(1):55-64.
doi: 10.1517/14740330903427951. PMID: 20001754.

Marleau AM, Lipton JH, Riordan NH, Ichim TE. Therapeutic use of Aldara in
chronic myeloid leukemia. J Transl Med. 2007 Jan 25;5:4. doi:
10.1186/1479-5876-5-4. PMID: 17254347; PMCID: PMC1790884.

Ichim TE, Alexandrescu DT, Solano F, Lara F, Campion Rde N, Paris E, Woods
EJ, Murphy MP, Dasanu CA, Patel AN, Marleau AM, Leal A, Riordan NH. Mesenchymal
stem cells as anti-inflammatories: implications for treatment of Duchenne
muscular dystrophy. Cell Immunol. 2010;260(2):75-82. doi:
10.1016/j.cellimm.2009.10.006. PMID: 19917503.

Mikirova NA, Jackson JA, Hunninghake R, Kenyon J, Chan KW, Swindlehurst CA,
Minev B, Patel AN, Murphy MP, Smith L, Alexandrescu DT, Ichim TE, Riordan NH.
Circulating endothelial progenitor cells: a new approach to anti-aging medicine?
J Transl Med. 2009 Dec 15;7:106. doi: 10.1186/1479-5876-7-106. PMID: 20003528;
PMCID: PMC2804590.

Riordan NH, Ichim TE, Min WP, Wang H, Solano F, Lara F, Alfaro M, Rodriguez
JP, Harman RJ, Patel AN, Murphy MP, Lee RR, Minev B. Non-expanded adipose
stromal vascular fraction cell therapy for multiple sclerosis. J Transl Med.
2009 Apr 24;7:29. doi: 10.1186/1479-5876-7-29. PMID: 19393041; PMCID:
PMC2679713.

Zhang Y, Fu J, Shi Y, Peng S, Cai Y, Zhan X, Song N, Liu Y, Wang Z, Yu Y,
Wang Y, Shi Q, Fu Y, Yuan K, Zhou N, Joshi R, Ichim TE, Min W. A new cancer
immunotherapy via simultaneous DC-mobilization and DC-targeted IDO gene
silencing using an immune-stimulatory nanosystem. Int J Cancer. 2018 Oct
15;143(8):2039-2052. doi: 10.1002/ijc.31588. Epub 2018 Aug 10. PMID: 29752722.

Li X, Lan X, Wang G, Liu Y, Zhao K, Lu SZ, Xu XX, Shi GG, Ye K, Zhang BR,
Zhao YM, Han HQ, Du CG, Ichim TE, Wang H. Skin Allografting Activates Anti-tumor
Immunity and Suppresses Growth of Colon Cancer in Mice. Transl Oncol. 2018
Aug;11(4):890-899. doi: 10.1016/j.tranon.2018.04.012. Epub 2018 May 21. PMID:
29793087; PMCID: PMC6041562.

Bockeria L, Bogin V, Bockeria O, Le T, Alekyan B, Woods EJ, Brown AA, Ichim
TE, Patel AN. Endometrial regenerative cells for treatment of heart failure: a
new stem cell enters the clinic. J Transl Med. 2013 Mar 5;11:56. doi:
10.1186/1479-5876-11-56. PMID: 23510656; PMCID: PMC3599750.

Ichim TE, Kesari S, Shafer K. Protection from chemotherapy- and antibiotic-
mediated dysbiosis of the gut microbiota by a probiotic with digestive enzymes
supplement. Oncotarget. 2018 Jul 20;9(56):30919-30935. doi:
10.18632/oncotarget.25778. PMID: 30112118; PMCID: PMC6089397.

Riordan NH, Chan K, Marleau AM, Ichim TE. Cord blood in regenerative
medicine: do we need immune suppression? J Transl Med. 2007 Jan 30;5:8. doi:
10.1186/1479-5876-5-8. PMID: 17261200; PMCID: PMC1796850.

Alexandrescu DT, Kauffman CL, Ichim TE, Riordan NH, Kabigting F, Dasanu CA.
Cutaneous sarcoidosis and malignancy: An association between sarcoidosis with
skin manifestations and systemic neoplasia. Dermatol Online J. 2011 Jan
15;17(1):2. PMID: 21272493.

Alexandrescu DT, Maslin B, Kauffman CL, Ichim TE, Dasanu CA. Malignant
melanoma in pigmented skin: does the current interventional model fit a
different clinical, histologic, and molecular entity? Dermatol Surg. 2013
Sep;39(9):1291-303. doi: 10.1111/dsu.12251. Epub 2013 Jun 24. PMID: 23795952.

Tullis RH, Duffin RP, Ichim TE, Joyce JA, Levin NW. Modeling hepatitis C
virus therapies combining drugs and lectin affinity plasmapheresis. Blood Purif.
2010;29(2):210-5. doi: 10.1159/000245649. Epub 2010 Jan 8. PMID: 20093829.

Ichim TE, Warbington T, Cristea O, Chin JL, Patel AN. Intracavernous
administration of bone marrow mononuclear cells: a new method of treating
erectile dysfunction? J Transl Med. 2013 Jun 9;11:139. doi:
10.1186/1479-5876-11-139. PMID: 23758954; PMCID: PMC3718667.

Dobrovolsky A, Ichim TE, Ma D, Kesari S, Bogin V. Xenon in the treatment of
panic disorder: an open label study. J Transl Med. 2017 Jun 13;15(1):137. doi:
10.1186/s12967-017-1237-1. PMID: 28610592; PMCID: PMC5470223.

Murphy MP, Wang H, Patel AN, Kambhampati S, Angle N, Chan K, Marleau AM,
Pyszniak A, Carrier E, Ichim TE, Riordan NH. Allogeneic endometrial regenerative
cells: an "Off the shelf solution" for critical limb ischemia? J Transl Med.
2008 Aug 19;6:45. doi: 10.1186/1479-5876-6-45. PMID: 18713449; PMCID:
PMC2533293.

Ichim TE, Harman RJ, Min WP, Minev B, Solano F, Rodriguez JP, Alexandrescu
DT, De Necochea-Campion R, Hu X, Marleau AM, Riordan NH. Autologous stromal
vascular fraction cells: a tool for facilitating tolerance in rheumatic disease.
Cell Immunol. 2010;264(1):7-17. doi: 10.1016/j.cellimm.2010.04.002. Epub 2010
Apr 8. PMID: 20537320.

Leal A, Ichim TE, Marleau AM, Lara F, Kaushal S, Riordan NH. Immune effects
of mesenchymal stem cells: implications for Charcot-Marie-Tooth disease. Cell
Immunol. 2008 May-Jun;253(1-2):11-5. doi: 10.1016/j.cellimm.2008.06.003. Epub
2008 Jul 15. PMID: 18627903.

Elabd C, Ichim TE, Miller K, Anneling A, Grinstein V, Vargas V, Silva FJ.
Comparing atmospheric and hypoxic cultured mesenchymal stem cell transcriptome:
implication for stem cell therapies targeting intervertebral discs. J Transl
Med. 2018 Aug 10;16(1):222. doi: 10.1186/s12967-018-1601-9. PMID: 30097061;
PMCID: PMC6086019.

Wagner SC, Ichim TE, Bogin V, Min WP, Silva F, Patel AN, Kesari S. Induction
and characterization of anti-tumor endothelium immunity elicited by ValloVax
therapeutic cancer vaccine. Oncotarget. 2017 Apr 25;8(17):28595-28613. doi:
10.18632/oncotarget.15563. PMID: 28404894; PMCID: PMC5438675.

Suzuki M, Zheng X, Zhang X, Zhang Y, Ichim TE, Min W. Regulation of allergy
with RNA interference. Crit Rev Immunol. 2009;29(6):443-68. doi:
10.1615/critrevimmunol.v29.i6.10. PMID: 20121695.

Darinskas A, Paskevicius M, Apanavicius G, Vilkevicius G, Labanauskas L,
Ichim TE, Rimdeika R. Stromal vascular fraction cells for the treatment of
critical limb ischemia: a pilot study. J Transl Med. 2017 Jun 19;15(1):143. doi:
10.1186/s12967-017-1243-3. Retraction in: J Transl Med. 2020 Feb 18;18(1):90.
PMID: 28629476; PMCID: PMC5477131.

Ichim TE, Solano F, Lara F, Rodriguez JP, Cristea O, Minev B, Ramos F, Woods
EJ, Murphy MP, Alexandrescu DT, Patel AN, Riordan NH. Combination stem cell
therapy for heart failure. Int Arch Med. 2010 Apr 14;3(1):5. doi:
10.1186/1755-7682-3-5. PMID: 20398245; PMCID: PMC3003238.

Ichim TE, Minev B, Braciak T, Luna B, Hunninghake R, Mikirova NA, Jackson
JA, Gonzalez MJ, Miranda-Massari JR, Alexandrescu DT, Dasanu CA, Bogin V, Ancans
J, Stevens RB, Markosian B, Koropatnick J, Chen CS, Riordan NH. Intravenous
ascorbic acid to prevent and treat cancer-associated sepsis? J Transl Med. 2011
Mar 4;9:25. doi: 10.1186/1479-5876-9-25. PMID: 21375761; PMCID: PMC3061919.

Zheng X, Suzuki M, Zhang X, Ichim TE, Zhu F, Ling H, Shunnar A, Wang MH,
Garcia B, Inman RD, Min WP. RNAi-mediated CD40-CD154 interruption promotes
tolerance in autoimmune arthritis. Arthritis Res Ther. 2010;12(1):R13. doi:
10.1186/ar2914. Epub 2010 Jan 26. PMID: 20102615; PMCID: PMC2875641.

Ichim TE, Solano F, Brenes R, Glenn E, Chang J, Chan K, Riordan NH.
Placental mesenchymal and cord blood stem cell therapy for dilated
cardiomyopathy. Reprod Biomed Online. 2008 Jun;16(6):898-905. doi:
10.1016/s1472-6483(10)60159-9. PMID: 18549704.

Ichim TE, Zhong Z, Mikirova NA, Jackson JA, Hunninghake R, Mansilla E, Marín
G, Núñez L, Patel AN, Angle N, Murphy MP, Dasanu CA, Alexandrescu DT, Bogin V,
Riordan NH. Circulating endothelial progenitor cells and erectile dysfunction:
possibility of nutritional intervention? Panminerva Med. 2010 Jun;52(2 Suppl
1):75-80. PMID: 20657539.

Wang H, Jin P, Sabatino M, Ren J, Civini S, Bogin V, Ichim TE, Stroncek DF.
Comparison of endometrial regenerative cells and bone marrow stromal cells. J
Transl Med. 2012 Oct 5;10:207. doi: 10.1186/1479-5876-10-207. PMID: 23038994;
PMCID: PMC3504519.

Zheng X, Suzuki M, Ichim TE, Zhang X, Sun H, Zhu F, Shunnar A, Garcia B,
Inman RD, Min W. Treatment of autoimmune arthritis using RNA interference-
modulated dendritic cells. J Immunol. 2010 Jun 1;184(11):6457-64. doi:
10.4049/jimmunol.0901717. Epub 2010 Apr 30. PMID: 20435931.

Dasanu CA, Clark BA 3rd, Ichim TE, Alexandrescu DT. Polycystic ovary
syndrome: focus on platelets and prothrombotic risk. South Med J. 2011
Mar;104(3):174-8. doi: 10.1097/SMJ.0b013e31820c0172. PMID: 21297528.

Mikirova NA, Kesari S, Ichim TE, Riordan NH. Effect of Infla-Kine
supplementation on the gene expression of inflammatory markers in peripheral
mononuclear cells and on C-reactive protein in blood. J Transl Med. 2017 Oct
20;15(1):213. doi: 10.1186/s12967-017-1315-4. PMID: 29058588; PMCID: PMC5651612.

Lu S, Shi G, Xu X, Wang G, Lan X, Sun P, Li X, Zhang B, Gu X, Ichim TE, Wang
H. Human endometrial regenerative cells alleviate carbon tetrachloride-induced
acute liver injury in mice. J Transl Med. 2016 Oct 22;14(1):300. doi:
10.1186/s12967-016-1051-1. PMID: 27770815; PMCID: PMC5075169.

Ichim TE, Li S, Ma H, Yurova YV, Szymanski JS, Patel AN, Kesari S, Min WP,
Wagner SC. Induction of tumor inhibitory anti-angiogenic response through
immunization with interferon Gamma primed placental endothelial cells:
ValloVax™. J Transl Med. 2015 Mar 14;13:90. doi: 10.1186/s12967-015-0441-0.
PMID: 25889119; PMCID: PMC4363400.

Suzuki M, Zheng X, Zhang X, Ichim TE, Sun H, Kubo N, Beduhn M, Shunnar A,
Garcia B, Min WP. Inhibition of allergic responses by CD40 gene silencing.
Allergy. 2009 Mar;64(3):387-97. doi: 10.1111/j.1398-9995.2008.01839.x. Epub 2009
Jan 28. PMID: 19175598.

Dasanu CA, Clark BA 3rd, Lahiri B, Ichim TE, Alexandrescu DT. Small cell
lung cancer with paraneoplastic lipase production. South Med J. 2010
Aug;103(8):819-22. doi: 10.1097/SMJ.0b013e3181e6369e. PMID: 20622741.

Riordan NH, Madrigal M, Reneau J, de Cupeiro K, Jiménez N, Ruiz S, Sanchez
N, Ichim TE, Silva F, Patel AN. Scalable efficient expansion of mesenchymal stem
cells in xeno free media using commercially available reagents. J Transl Med.
2015 Jul 17;13:232. doi: 10.1186/s12967-015-0561-6. PMID: 26183703; PMCID:
PMC4504159.

Zhang X, Beduhn M, Zheng X, Lian D, Chen D, Li R, Siu LK, Marleau A, French
PW, Ichim TE, Min WP. Induction of alloimmune tolerance in heart transplantation
through gene silencing of TLR adaptors. Am J Transplant. 2012
Oct;12(10):2675-88. doi: 10.1111/j.1600-6143.2012.04196.x. Epub 2012 Jul 23.
PMID: 22823145.

Ichim TE, Patel AN, Shafer KA. Experimental support for the effects of a
probiotic/digestive enzyme supplement on serum cholesterol concentrations and
the intestinal microbiome. J Transl Med. 2016 Jun 22;14(1):184. doi:
10.1186/s12967-016-0945-2. PMID: 27333764; PMCID: PMC4918082.

Han X, Meng X, Yin Z, Rogers A, Zhong J, Rillema P, Jackson JA, Ichim TE,
Minev B, Carrier E, Patel AN, Murphy MP, Min WP, Riordan NH. Inhibition of
intracranial glioma growth by endometrial regenerative cells. Cell Cycle. 2009
Feb 15;8(4):606-10. doi: 10.4161/cc.8.4.7731. Epub 2009 Mar 2. PMID: 19197154.

Suzuki M, Zheng X, Zhang X, Zhang ZX, Ichim TE, Sun H, Nakamura Y, Inagaki
A, Beduhn M, Shunnar A, Garcia B, Min WP. A novel allergen-specific therapy for
allergy using CD40-silenced dendritic cells. J Allergy Clin Immunol. 2010
Mar;125(3):737-43, 743.e1-743.e6. doi: 10.1016/j.jaci.2009.11.042. PMID:
20226305.

Mikirova NA, Ichim TE, Riordan NH. Anti-angiogenic effect of high doses of
ascorbic acid. J Transl Med. 2008 Sep 12;6:50. doi: 10.1186/1479-5876-6-50.
PMID: 18789157; PMCID: PMC2562367.

Suzuki M, Zheng X, Zhang X, Ichim TE, Beduhn ME, Min W. Oligonucleotide
based-strategies for allergy with special reference to siRNA. Expert Opin Biol
Ther. 2009 Apr;9(4):441-50. doi: 10.1517/14712590902841924. PMID: 19344281.

Meng X, Ichim TE, Zhong J, Rogers A, Yin Z, Jackson J, Wang H, Ge W, Bogin
V, Chan KW, Thébaud B, Riordan NH. Endometrial regenerative cells: a novel stem
cell population. J Transl Med. 2007 Nov 15;5:57. doi: 10.1186/1479-5876-5-57.
PMID: 18005405; PMCID: PMC2212625.

Jiang N, Zhang X, Zheng X, Chen D, Zhang Y, Siu LK, Xin HB, Li R, Zhao H,
Riordan N, Ichim TE, Quan D, Jevnikar AM, Chen G, Min W. Targeted gene silencing
of TLR4 using liposomal nanoparticles for preventing liver ischemia reperfusion
injury. Am J Transplant. 2011 Sep;11(9):1835-44. doi:
10.1111/j.1600-6143.2011.03660.x. Epub 2011 Jul 27. PMID: 21794086.

Zhong Z, Patel AN, Ichim TE, Riordan NH, Wang H, Min WP, Woods EJ, Reid M,
Mansilla E, Marin GH, Drago H, Murphy MP, Minev B. Feasibility investigation of
allogeneic endometrial regenerative cells. J Transl Med. 2009 Feb 20;7:15. doi:
10.1186/1479-5876-7-15. PMID: 19232091; PMCID: PMC2649897.

Zhong Z, Kusznieruk KP, Popov IA, Riordan NH, Izadi H, Yijian L, Sher S,
Szczurko OM, Agadjanyan MG, Tullis RH, Harandi A, Reznik BN, Mamikonyan GV,
Ichim TE. Induction of antitumor immunity through xenoplacental immunization. J
Transl Med. 2006 May 25;4:22. doi: 10.1186/1479-5876-4-22. PMID: 16725035;
PMCID: PMC1482718.

Ichim TE, Solano F, Lara F, Paris E, Ugalde F, Rodriguez JP, Minev B, Bogin
V, Ramos F, Woods EJ, Murphy MP, Patel AN, Harman RJ, Riordan NH. Feasibility of
combination allogeneic stem cell therapy for spinal cord injury: a case report.
Int Arch Med. 2010 Nov 11;3:30. doi: 10.1186/1755-7682-3-30. PMID: 21070647;
PMCID: PMC2989319.

Chen S, Wei Q, Li J, Xiang Y, Guo H, Ichim TE, Chen S, Chen G. A simple and
reliable method to blood type monkeys using serum samples. Transpl Int. 2009
Oct;22(10):999-1004. doi: 10.1111/j.1432-2277.2009.00859.x. Epub 2009 Mar 9.
PMID: 19298252.

Zhong Z, Dong Z, Lu Q, Li Y, Lv C, Zhu X, Zhao X, Zhang X, Morales F, Ichim
TE. Successful penile replantation with adjuvant hyperbaric oxygen treatment.
Urology. 2007 May;69(5):983.e3-5. doi: 10.1016/j.urology.2007.02.024. PMID:
17482954.

Alexandrescu DT, Ichim TE, Kabigting F, Dasanu CA. Acute gout during
treatment with paclitaxel for metastatic melanoma. Rheumatology (Oxford). 2009
Jul;48(7):862-3. doi: 10.1093/rheumatology/kep123. Epub 2009 May 20. PMID:
19458161.

Ichim TE, Zhong R, Min WP. Prevention of allograft rejection by in vitro
generated tolerogenic dendritic cells. Transpl Immunol. 2003 Jul-
Sep;11(3-4):295-306. doi: 10.1016/S0966-3274(03)00048-0. PMID: 12967783.

Dasanu CA, Ichim TE, Alexandrescu DT. Muehrcke's lines (Leukonychia striata)
due to transretinoic acid therapy for acute promyelocytic leukemia. J Oncol
Pharm Pract. 2013 Dec;19(4):377-9. doi: 10.1177/1078155212468923. Epub 2013 Jan
4. PMID: 23292969.

Dasanu CA, Bauer F, Ichim TE, Vyas D, Ek K, Alexandrescu DT. Rapidly fatal
acute ATLL emerging after methotrexate therapy for disseminated psoriasis. Clin
Lymphoma Myeloma Leuk. 2012 Feb;12(1):76-8. doi: 10.1016/j.clml.2011.02.010.
Epub 2011 Jun 11. PMID: 21729685.

Xia X, Zhang X, Huang X, Ichim TE, Li M, Luke P, Min W. Anti-CD(45)RB
monoclonal antibody induces immunologic toleration by suppressing dendritic
cells. Transpl Immunol. 2009 Jul;21(3):136-9. doi: 10.1016/j.trim.2009.04.001.
Epub 2009 Apr 21. PMID: 19389475.

Feng B, Chen G, Zheng X, Sun H, Zhang X, Zhang ZX, Xiang Y, Ichim TE, Garcia
B, Luke P, Jevnikar AM, Min WP. Small interfering RNA targeting RelB protects
against renal ischemia-reperfusion injury. Transplantation. 2009 May
15;87(9):1283-9. doi: 10.1097/TP.0b013e3181a1905e. PMID: 19424026.

Yang WZ, Zhang Y, Wu F, Min WP, Minev B, Zhang M, Luo XL, Ramos F, Ichim TE,
Riordan NH, Hu X. Safety evaluation of allogeneic umbilical cord blood
mononuclear cell therapy for degenerative conditions. J Transl Med. 2010 Aug
3;8:75. doi: 10.1186/1479-5876-8-75. PMID: 20682053; PMCID: PMC2922090.

Abusamra AJ, Zhong Z, Zheng X, Li M, Ichim TE, Chin JL, Min WP. Tumor
exosomes expressing Fas ligand mediate CD8+ T-cell apoptosis. Blood Cells Mol
Dis. 2005 Sep-Oct;35(2):169-73. doi: 10.1016/j.bcmd.2005.07.001. PMID: 16081306.

Zheng X, Vladau C, Zhang X, Suzuki M, Ichim TE, Zhang ZX, Li M, Carrier E,
Garcia B, Jevnikar AM, Min WP. A novel in vivo siRNA delivery system
specifically targeting dendritic cells and silencing CD40 genes for
immunomodulation. Blood. 2009 Mar 19;113(12):2646-54. doi:
10.1182/blood-2008-04-151191. Epub 2009 Jan 22. PMID: 19164600.

Mikirova NA, Jackson JA, Hunninghake R, Kenyon J, Chan KW, Swindlehurst CA,
Minev B, Patel AN, Murphy MP, Smith L, Ramos F, Ichim TE, Riordan NH.
Nutraceutical augmentation of circulating endothelial progenitor cells and
hematopoietic stem cells in human subjects. J Transl Med. 2010 Apr 8;8:34. doi:
10.1186/1479-5876-8-34. PMID: 20377846; PMCID: PMC2862021.

Kanai N, Min WP, Ichim TE, Wang H, Zhong R. Th1/Th2 xenogenic antibody
responses are associated with recipient dendritic cells. Microsurgery.
2007;27(4):234-9. doi: 10.1002/micr.20342. PMID: 17477419.

Dasanu CA, Mesologites T, Homsi S, Ichim TE, Alexandrescu DT. Chronic
lymphocytic leukemia presenting with cholecystitis-like symptoms and gallbladder
wall invasion. South Med J. 2010 May;103(5):482-4. doi:
10.1097/SMJ.0b013e3181d7e38f. PMID: 20375943.

Yang WZ, Zhang Y, Wu F, Zhang M, Cho SC, Li CZ, Li SH, Shu GJ, Sheng YX,
Zhao N, Tang Y, Jiang S, Jiang S, Gandjian M, Ichim TE, Hu X. Human umbilical
cord blood-derived mononuclear cell transplantation: case series of 30 subjects
with hereditary ataxia. J Transl Med. 2011 May 16;9:65. doi:
10.1186/1479-5876-9-65. PMID: 21575250; PMCID: PMC3112442.

Jiang N, Zhang X, Zheng X, Chen D, Siu K, Wang H, Ichim TE, Quan D,
McAlister V, Chen G, Min WP. A novel in vivo siRNA delivery system specifically
targeting liver cells for protection of ConA-induced fulminant hepatitis. PLoS
One. 2012;7(9):e44138. doi: 10.1371/journal.pone.0044138. Epub 2012 Sep 6. PMID:
22970170; PMCID: PMC3435394.

McKnight AL, Minkoff LA, Sutton DL, Thomsen BV, Habecker PL, Sweeney RW,
Smith G, Dasanu CA, Ichim TE, Alexandrescu DT, Stutman JM. Generalized cerebral
atrophy seen on MRI in a naturally exposed animal model for Creutzfeldt-Jakob
disease. J Transl Med. 2010 Nov 26;8:125. doi: 10.1186/1479-5876-8-125. PMID:
21108848; PMCID: PMC3009697.

Zheng X, Koropatnick J, Chen D, Velenosi T, Ling H, Zhang X, Jiang N,
Navarro B, Ichim TE, Urquhart B, Min W. Silencing IDO in dendritic cells: a
novel approach to enhance cancer immunotherapy in a murine breast cancer model.
Int J Cancer. 2013 Feb 15;132(4):967-77. doi: 10.1002/ijc.27710. Epub 2012 Jul
20. PMID: 22870862.

Zheng X, Lian D, Wong A, Bygrave M, Ichim TE, Khoshniat M, Zhang X, Sun H,
De Zordo T, Lacefield JC, Garcia B, Jevnikar AM, Min WP. Novel small interfering
RNA-containing solution protecting donor organs in heart transplantation.
Circulation. 2009 Sep 22;120(12):1099-107, 1 p following 1107. doi:
10.1161/CIRCULATIONAHA.108.787390. Epub 2009 Sep 8. PMID: 19738144.

Zhu M, Zhang W, Liu F, Wang L, Liu B, Chen D, Zhu XH, Zhang WJ, Ichim TE,
Chen ZS, Zhou P, Chen S, Chen G. Resistance to anti-xenogeneic response by
combining alpha-Gal silencing with HO-1 upregulation. Transpl Immunol. 2008
Jul;19(3-4):202-8. doi: 10.1016/j.trim.2008.06.002. Epub 2008 Jul 1. PMID:
18598766.

Chan RC, Gutierrez B, Ichim TE, Lin F. Enhancement of DNA cancer vaccine
efficacy by combination with anti-angiogenesis in regression of established
subcutaneous B16 melanoma. Oncol Rep. 2009 Nov;22(5):1197-203. doi:
10.3892/or_00000555. PMID: 19787240.

Yin Z, Chen D, Hu F, Ruan Y, Li J, Wang L, Xiang Y, Xie L, Wang X, Ichim TE,
Chen S, Chen G. Cotransplantation with xenogenetic neonatal porcine sertoli
cells significantly prolongs islet allograft survival in nonimmunosuppressive
rats. Transplantation. 2009 Aug 15;88(3):339-45. doi:
10.1097/TP.0b013e3181ae5dcf. PMID: 19667935.

Ichim TE, Zhong Z, Kaushal S, Zheng X, Ren X, Hao X, Joyce JA, Hanley HH,
Riordan NH, Koropatnick J, Bogin V, Minev BR, Min WP, Tullis RH. Exosomes as a
tumor immune escape mechanism: possible therapeutic implications. J Transl Med.
2008 Jul 22;6:37. doi: 10.1186/1479-5876-6-37. PMID: 18644158; PMCID:
PMC2504474.

Li J, Gong Q, Zhong S, Wang L, Guo H, Xiang Y, Ichim TE, Wang CY, Chen S,
Gong F, Chen G. Neutralization of the extracellular HMGB1 released by ischaemic
damaged renal cells protects against renal ischaemia-reperfusion injury. Nephrol
Dial Transplant. 2011 Feb;26(2):469-78. doi: 10.1093/ndt/gfq466. Epub 2010 Aug
2. PMID: 20679140.

Ichim TE, Popov IA, Riordan NH, Izadi H, Zhong Z, Yijian L, Sher S, Oleinik
EK. A novel method of modifying immune responses by vaccination with lipiodol-
siRNA mixtures. J Transl Med. 2006 Jan 3;4:2. doi: 10.1186/1479-5876-4-2. PMID:
16390542; PMCID: PMC1343589.

Wang H, Ge W, Arp J, Zassoko R, Liu W, Ichim TE, Jiang J, Jevnikar AM,
Garcia B. Free bone graft attenuates acute rejection and in combination with
cyclosporin a leads to indefinite cardiac allograft survival. J Immunol. 2009
May 15;182(10):5970-81. doi: 10.4049/jimmunol.0801037. PMID: 19414748.

Popov I, Li M, Zheng X, San H, Zhang X, Ichim TE, Suzuki M, Feng B, Vladau
C, Zhong R, Garcia B, Strejan G, Inman RD, Min WP. Preventing autoimmune
arthritis using antigen-specific immature dendritic cells: a novel tolerogenic
vaccine. Arthritis Res Ther. 2006;8(5):R141. doi: 10.1186/ar2031. PMID:
16911769; PMCID: PMC1779442.

Yin Z, Wang L, Xiang Y, Ruan Y, Li J, Wang X, Ichim TE, Chen S, Chen G.
Resistance of neonatal porcine Sertoli cells to human xenoantibody and
complement-mediated lysis is associated with low expression of alpha-Gal and
high production of clusterin and CD59. Xenotransplantation. 2010 May-
Jun;17(3):215-23. doi: 10.1111/j.1399-3089.2010.00581.x. PMID: 20636542.

Dougherty CJ, Ichim TE, Liu L, Reznik G, Min WP, Ghochikyan A, Agadjanyan
MG, Reznik BN. Selective apoptosis of breast cancer cells by siRNA targeting of
BORIS. Biochem Biophys Res Commun. 2008 May 23;370(1):109-12. doi:
10.1016/j.bbrc.2008.03.040. Epub 2008 Mar 18. PMID: 18355444.

Hill JA, Ichim TE, Kusznieruk KP, Li M, Huang X, Yan X, Zhong R, Cairns E,
Bell DA, Min WP. Immune modulation by silencing IL-12 production in dendritic
cells using small interfering RNA. J Immunol. 2003 Jul 15;171(2):691-6. doi:
10.4049/jimmunol.171.2.691. Erratum in: J Immunol. 2003 Sep 15;171(6):3303.
PMID: 12847235.

Mansilla E, Spretz R, Larsen G, Nuñez L, Drago H, Sturla F, Marin GH, Roque
G, Martire K, Díaz Aquino V, Bossi S, Gardiner C, Lamonega R, Lauzada N, Cordone
J, Raimondi JC, Tau JM, Biasi NR, Marini JE, Patel AN, Ichim TE, Riordan N,
Maceira A. Outstanding survival and regeneration process by the use of
intelligent acellular dermal matrices and mesenchymal stem cells in a burn pig
model. Transplant Proc. 2010 Dec;42(10):4275-8. doi:
10.1016/j.transproceed.2010.09.132. PMID: 21168681.

Suzuki M, Zheng X, Zhang X, Li M, Vladau C, Ichim TE, Sun H, Min LR, Garcia
B, Min WP. Novel vaccination for allergy through gene silencing of CD40 using
small interfering RNA. J Immunol. 2008 Jun 15;180(12):8461-9. doi:
10.4049/jimmunol.180.12.8461. PMID: 18523314.

Zhang X, Li M, Lian D, Zheng X, Zhang ZX, Ichim TE, Xia X, Huang X, Vladau
C, Suzuki M, Garcia B, Jevnikar AM, Min WP. Generation of therapeutic dendritic
cells and regulatory T cells for preventing allogeneic cardiac graft rejection.
Clin Immunol. 2008 Jun;127(3):313-21. doi: 10.1016/j.clim.2008.01.013. Epub 2008
Mar 20. PMID: 18358783.

Min WP, Zhou D, Ichim TE, Strejan GH, Xia X, Yang J, Huang X, Garcia B,
White D, Dutartre P, Jevnikar AM, Zhong R. Inhibitory feedback loop between
tolerogenic dendritic cells and regulatory T cells in transplant tolerance. J
Immunol. 2003 Feb 1;170(3):1304-12. doi: 10.4049/jimmunol.170.3.1304. PMID:
12538690.

Loukinov D, Ghochikyan A, Mkrtichyan M, Ichim TE, Lobanenkov VV, Cribbs DH,
Agadjanyan MG. Antitumor efficacy of DNA vaccination to the epigenetically
acting tumor promoting transcription factor BORIS and CD80 molecular adjuvant. J
Cell Biochem. 2006 Aug 1;98(5):1037-43. doi: 10.1002/jcb.20953. PMID: 16741971.

Alexandrescu DT, Ichim TE, Riordan NH, Marincola FM, Dasanu CA. IFN-
conditioned dendritic cells for the therapy of melanoma: what is missing? J
Immunother. 2011 Oct;34(8):607-609. doi: 10.1097/CJI.0b013e31822b9ffc. PMID:
22025902; PMCID: PMC3184394.

Wang H, Hosiawa KA, Min W, Yang J, Zhang X, Garcia B, Ichim TE, Zhou D,
Lian D, Kelvin DJ, Zhong R. Cytokines regulate the pattern of rejection and
susceptibility to cyclosporine therapy in different mouse recipient strains
after cardiac allografting. J Immunol. 2003 Oct 1;171(7):3823-36. doi:
10.4049/jimmunol.171.7.3823. PMID: 14500684.

Ghochikyan A, Mkrtichyan M, Loukinov D, Mamikonyan G, Pack SD, Movsesyan N,
Ichim TE, Cribbs DH, Lobanenkov VV, Agadjanyan MG. Elicitation of T cell
responses to histologically unrelated tumors by immunization with the novel
cancer-testis antigen, brother of the regulator of imprinted sites. J Immunol.
2007 Jan 1;178(1):566-73. doi: 10.4049/jimmunol.178.1.566. PMID: 17182597;
PMCID: PMC2377412.

Mkrtichyan M, Ghochikyan A, Loukinov D, Davtyan H, Ichim TE, Cribbs DH,
Lobanenkov VV, Agadjanyan MG. DNA, but not protein vaccine based on mutated
BORIS antigen significantly inhibits tumor growth and prolongs the survival of
mice. Gene Ther. 2008 Jan;15(1):61-4. doi: 10.1038/sj.gt.3303044. Epub 2007 Nov
1. PMID: 17972923; PMCID: PMC2497453.

Mamikonyan G, Kiyatkin A, Movsesyan N, Mkrtichyan M, Ghochikyan A,
Petrushina I, Hwang J, Ichim TE, Keledjian H, Agadjanyan MG. Detection of the
active components of calf thymus nuclear proteins (TNP), histones that are
binding with high affinity to HIV-1 envelope proteins and CD4 molecules. Curr
HIV Res. 2008 Jun;6(4):318-26. doi: 10.2174/157016208785132545. PMID: 18691030.

Yang J, Bernier SM, Ichim TE, Li M, Xia X, Zhou D, Huang X, Strejan GH,
White DJ, Zhong R, Min WP. LF15-0195 generates tolerogenic dendritic cells by
suppression of NF-kappaB signaling through inhibition of IKK activity. J Leukoc
Biol. 2003 Sep;74(3):438-47. doi: 10.1189/jlb.1102582. PMID: 12949248.

Min WP, Zhou D, Ichim TE, Xia X, Zhang X, Yang J, Huang X, Garcia B,
Dutartre P, Jevnikar AM, Strejan GH, Zhong R. Synergistic tolerance induced by
LF15-0195 and anti-CD45RB monoclonal antibody through suppressive dendritic
cells. Transplantation. 2003 Apr 27;75(8):1160-5. doi:
10.1097/01.TP.0000061792.78914.52. PMID: 12717196.

Khandaker MH, Kadhim SA, Ichim TE, Howson-Jan K, Chin J, Singhal SK.
Prevention of bladder tumor formation in mice by a novel bone marrow-derived
factor, reptimed. Anticancer Res. 2000 Jan-Feb;20(1A):183-9. PMID: 10769653.
curiousman
Posts: 26
Joined: Fri Dec 24, 2021 3:09 am

Re: So when is Jadicell going to start the phase 3 trial for severe covid-19?

Post by curiousman »

Tim,

Have you personally ever met Neil Riordan?
User avatar
TimGDixon
Posts: 3163
Joined: Fri Jun 26, 2020 4:36 am

Re: So when is Jadicell going to start the phase 3 trial for severe covid-19?

Post by TimGDixon »

No I never have.
curiousman
Posts: 26
Joined: Fri Dec 24, 2021 3:09 am

Re: So when is Jadicell going to start the phase 3 trial for severe covid-19?

Post by curiousman »

TimGDixon wrote: Sun Dec 26, 2021 4:27 am No I never have.

What does the O stand for in TSOI?
User avatar
TimGDixon
Posts: 3163
Joined: Fri Jun 26, 2020 4:36 am

Re: So when is Jadicell going to start the phase 3 trial for severe covid-19?

Post by TimGDixon »

I have never had any ask that - O is the O out of sOlutions, as in therapeutic solutions - when I requested a symbol from FINRA in 2011 I wanted TSOL but it was not available and we were instead given TSOI.
curiousman wrote: Sun Dec 26, 2021 4:42 am
TimGDixon wrote: Sun Dec 26, 2021 4:27 am No I never have.

What does the O stand for in TSOI?
User avatar
TimGDixon
Posts: 3163
Joined: Fri Jun 26, 2020 4:36 am

Re: So when is Jadicell going to start the phase 3 trial for severe covid-19?

Post by TimGDixon »

Her is an update on another use of MSC's in CTE patients.
https://therapeuticsolutionsint.com/the ... halopathy/
cablejohn45
Posts: 54
Joined: Tue Jun 22, 2021 12:33 pm

Re: So when is Jadicell going to start the phase 3 trial for severe covid-19?

Post by cablejohn45 »

Do ur own DD O NEVER MIND HERE

TIM THE MAN viewtopic.php?p=11043#p11043
Post Reply